With this acquisition, DKSH intends to strengthen its technology division for scientific instruments.

The closing of the transaction is expected during the fourth quarter of 2023. Financial details of the deal were not disclosed.

Established 2003 and based in Melbourne, Bio-Strategy generates net sales of more than CHF 40 million Swiss francs. With a team of over 100 people, the company serves renowned blue-chip clients and distributes products and services to around 1,200 customers. Bio-Strategy’s management team and employees will join DKSH’s business unit Technology.

Hanno Elbraechter, head of the business unit Technology at DKSH, commented: “I am delighted with the acquisition of Bio-Strategy as an important addition to DKSH. The specific industry and application knowledge of the company will help us to solidify our position in two of Asia Pacific’s key markets. While complementing both DKSH Technology’s product portfolio and regional presence, the acquired expertise will enable us to create added value for our clients and customers.”

John Chesterfield, CEO of Bio-Strategy, added: “We are pleased about the combination with DKSH, one of Asia’s leading technology distribution players, marking the next big step in our 20-year journey. In addition to a wider regional reach and an enlarged product and service portfolio, our clients, customers, employees, and business partners will benefit from various synergies. We are excited about our shared future, to leverage our common expertise and to continue successfully serving our stakeholders.”